Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Coeptis Therapeutics Holdings (COEPW) Liabilities and Shareholders Equity (2021 - 2025)

Coeptis Therapeutics Holdings has reported Liabilities and Shareholders Equity over the past 5 years, most recently at $16.2 million for Q4 2025.

  • Quarterly results put Liabilities and Shareholders Equity at $16.2 million for Q4 2025, up 81.33% from a year ago — trailing twelve months through Dec 2025 was $56.0 million (up 115.66% YoY), and the annual figure for FY2025 was $16.2 million, up 81.33%.
  • Liabilities and Shareholders Equity for Q4 2025 was $16.2 million at Coeptis Therapeutics Holdings, up from $14.2 million in the prior quarter.
  • Over the last five years, Liabilities and Shareholders Equity for COEPW hit a ceiling of $76.6 million in Q1 2021 and a floor of $3.9 million in Q1 2024.
  • Median Liabilities and Shareholders Equity over the past 5 years was $10.6 million (2024), compared with a mean of $24.5 million.
  • Biggest five-year swings in Liabilities and Shareholders Equity: plummeted 92.18% in 2023 and later surged 245.45% in 2025.
  • Coeptis Therapeutics Holdings' Liabilities and Shareholders Equity stood at $6.8 million in 2021, then increased by 17.0% to $7.9 million in 2022, then plummeted by 42.25% to $4.6 million in 2023, then surged by 94.89% to $8.9 million in 2024, then surged by 81.33% to $16.2 million in 2025.
  • The last three reported values for Liabilities and Shareholders Equity were $16.2 million (Q4 2025), $14.2 million (Q3 2025), and $12.2 million (Q2 2025) per Business Quant data.